All In Biotech

Drug Trial Radar · NCT01500278

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

A Multicenter, Single-blind, Randomized Parallel-group Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis Responding Inadequately to Methotrexate

Last checked: Nov 20, 2026Latest source record: Jul 31, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 915 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

915

Actual

Start

Dec 2011

Primary completion

Nov 2015

Study completion Jan 2016

Sponsor

Lead sponsor
UCB Pharma SAUCB
Sponsor type
Industry
Collaborators
Parexel
First posted
Dec 28, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is conducted to evaluate the short (12 Weeks) and long term (104 Weeks) efficacy of Certolizumab Pegol compared with Adalimumab both in combination with Methotrexate (MTX) in the treatment of moderate to severe Rheumatoid Arthritis (RA) that is not responding adequately to MTX.

Conditions

  • Rheumatoid Arthritis

Interventions

  • Certolizumab Pegol (CZP)Biological

    * Active substance: an injectable volume of 1 ml solution for injection CZP * Pharmaceutical form: prefilled syringes CZP * Concentration: 200 mg/ml CZP * Route of Administration: injections will be given subcutaneously: loading dose of CZP 400 mg at Baseline, and Weeks 2 and 4, followed by a maintenance dose of 200 mg every 2 weeks through Week 102 or withdrawal.

  • Adalimumab (ADA)Biological

    * Active substance: an injectable volume of 0.8 ml solution for injection ADA * Pharmaceutical form: prefilled syringes ADA * Concentration: 40 mg/0.8 ml ADA * Route of Administration: injections will be given subcutaneously. ADA 40 mg plus an injection with Placebo (to preserve blind) at Baseline, and Weeks 2 and 4, followed by ADA 40 mg every 2 weeks through Week 102 or withdrawal.

  • Methotrexate (MTX)Drug

    * Active substance: Methotrexate * Pharmaceutical form: oral tablet * Concentration: 15-25 mg/week * Route of Administration: MTX orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Who Met the American College of Rheumatology 20 % (ACR20) Criteria at Week 12Time frame: Week 12
  2. Percentage of Subjects Who Had a Disease Activity Score 28 [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) ≤ 3.2 at Week 104Time frame: Week 104

Locations

175 sites in 20 countries. Site status is shown where the registry gives one.

  • 141

    Birmingham, Alabama

  • 214

    Tuscaloosa, Alabama

  • 159

    Tucson, Arizona

  • 152

    Hot Springs, Arkansas

  • 147

    Covina, California

  • 161

    Fullerton, California

  • 217

    La Mesa, California

  • 149

    Los Angeles, California

  • 144

    Menifee, California

  • 185

    Roseville, California

  • 208

    Sacramento, California

  • 189

    Van Nuys, California

  • 148

    Whittier, California

  • 220

    Lewes, Delaware

  • 142

    Aventura, Florida

  • 216

    Fort Lauderdale, Florida

  • 162

    Gainesville, Florida

  • 209

    Vero Beach, Florida

  • 145

    Coeur d'Alene, Idaho

  • 202

    Maywood, Illinois

  • 134

    Lexington, Kentucky

  • 178

    Baltimore, Maryland

  • 137

    Battle Creek, Michigan

  • 153

    Detroit, Michigan

  • 155

    Lansing, Michigan

  • 204

    Eagan, Minnesota

  • 180

    Rochester, Minnesota

  • 143

    Saint Louis Park, Minnesota

  • 135

    Omaha, Nebraska

  • 170

    Reno, Nevada

  • 201

    Teaneck, New Jersey

  • 150

    Voorhees Township, New Jersey

  • 205

    Albuquerque, New Mexico

  • 154

    Albany, New York

  • 136

    Brooklyn, New York

  • 219

    Orchard Park, New York

  • 207

    Plainview, New York

  • 167

    Syracuse, New York

  • 140

    Cincinnati, Ohio

  • 184

    Oklahoma City, Oklahoma

Showing 40 of 175 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.